CCS
ANAC

Crosspoint Capital Strategies’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Crosspoint Capital Strategies’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-138
Closed -$11K – 998
2015
Q2 		$11K Buy
138
+16
+13% +$1.05K ﹤0.01% 516
2015
Q1 		$7K Sell
122
-40
-25% -$1.7K ﹤0.01% 418
2014
Q4 		$5K Buy
+162
New +$4.86K ﹤0.01% 627

Other funds holding ANAC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM

Crosspoint Capital Strategies's ANAC Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q3 2015, closing a stake of 138 shares — an estimated $11K sold.

Crosspoint Capital Strategies first reported a position in ANAC in Q4 2014 and held it in 3 quarters. The position peaked at $11K in Q2 2015. 213 funds tracked by Wall St. Rank hold ANAC as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 138 ANACOR PHARMACEUTICALS INC COM shares in Q3 2015, an estimated $11K.
  • Crosspoint Capital Strategies first reported a position in ANACOR PHARMACEUTICALS INC COM in Q4 2014 and held it in 3 quarters.
  • Crosspoint Capital Strategies's ANACOR PHARMACEUTICALS INC COM position peaked at $11K in Q2 2015.
  • 213 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.